MicroPort CardioFlow Medtech Corporation

SEHK:2160 Rapporto sulle azioni

Cap. di mercato: HK$2.1b

MicroPort CardioFlow Medtech Gestione

Gestione criteri di controllo 2/4

MicroPort CardioFlow Medtech Il CEO è Ruinian Zhang, nominato in Mar2025, ha un mandato di meno di un anno. possiede direttamente 0.004% delle azioni della società, per un valore di HK$ 77.39K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.6 anni e 4.3 anni.

Informazioni chiave

Ruinian Zhang

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEOless than a year
Proprietà del CEO0.004%
Durata media del management4.6yrs
Durata media del Consiglio di amministrazione4.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Take Care Before Jumping Onto MicroPort CardioFlow Medtech Corporation (HKG:2160) Even Though It's 37% Cheaper

Apr 08
Take Care Before Jumping Onto MicroPort CardioFlow Medtech Corporation (HKG:2160) Even Though It's 37% Cheaper

Revenues Tell The Story For MicroPort CardioFlow Medtech Corporation (HKG:2160) As Its Stock Soars 29%

Feb 10
Revenues Tell The Story For MicroPort CardioFlow Medtech Corporation (HKG:2160) As Its Stock Soars 29%

MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

Sep 27
MicroPort CardioFlow Medtech Corporation (HKG:2160) Stocks Shoot Up 34% But Its P/S Still Looks Reasonable

After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Sep 27
After Leaping 34% MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares Are Not Flying Under The Radar

Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?

Aug 07
Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 43%?

Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding

Jun 19
Some MicroPort CardioFlow Medtech Corporation (HKG:2160) Shareholders Look For Exit As Shares Take 26% Pounding

MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

May 29
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

Apr 05
MicroPort CardioFlow Medtech Corporation (HKG:2160) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

Feb 23
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued

Jan 18
An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 37% Undervalued

Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth

Oct 04
Companies Like MicroPort CardioFlow Medtech (HKG:2160) Are In A Position To Invest In Growth

Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%

May 31
Not Many Are Piling Into MicroPort CardioFlow Medtech Corporation (HKG:2160) Stock Yet As It Plummets 27%

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

May 23
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts

Apr 06
The MicroPort CardioFlow Medtech Corporation (HKG:2160) Analysts Have Been Trimming Their Sales Forecasts

MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

Feb 08
MicroPort CardioFlow Medtech (HKG:2160) Is In A Good Position To Deliver On Growth Plans

We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

Oct 18
We Think MicroPort CardioFlow Medtech (HKG:2160) Can Afford To Drive Business Growth

We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate

Jun 30
We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate

Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

Apr 04
Analysts Just Made A Major Revision To Their MicroPort CardioFlow Medtech Corporation (HKG:2160) Revenue Forecasts

MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 03
MicroPort CardioFlow Medtech Corporation (HKG:2160) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued

Jan 21
An Intrinsic Calculation For MicroPort CardioFlow Medtech Corporation (HKG:2160) Suggests It's 49% Undervalued

Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?

Sep 05
Are Investors Undervaluing MicroPort CardioFlow Medtech Corporation (HKG:2160) By 24%?

We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn

Jun 07
We're Not Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn

Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)

May 03
Market Sentiment Around Loss-Making MicroPort CardioFlow Medtech Corporation (HKG:2160)

AMMINISTRATORE DELEGATO

Ruinian Zhang (60 yo)

less than a year

Mandato

Mr. Ruinian Zhang is President, GM & Executive Director of MicroPort CardioFlow Medtech Corporation from March 27, 2025. Mr. Zhang has many years of experience in the fields of cardiovascular, general surg...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Luying Yan
VP & Executive Director4.7yrsCN¥2.19m0.067%
HK$ 1.4m
Liang Zhao
Executive Director & First VP of Total Solutions3yrsCN¥2.27m0.071%
HK$ 1.5m
Ruinian Zhang
Presidentless than a yearNessun dato0.0037%
HK$ 77.4k
Xiangmei Li
Joint Company Secretary4.6yrsNessun datoNessun dato
Lok Yee Chan
Joint Company Secretary4.6yrsNessun datoNessun dato

4.6yrs

Durata media

43yo

Età media

Gestione esperta: Il team dirigenziale di 2160 è considerato esperto (durata media dell'incarico 4.6 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Luying Yan
VP & Executive Director4.7yrsCN¥2.19m0.067%
HK$ 1.4m
Liang Zhao
Executive Director & First VP of Total Solutions3yrsCN¥2.27m0.071%
HK$ 1.5m
Ruinian Zhang
Presidentless than a yearNessun dato0.0037%
HK$ 77.4k
Jonathan H. Chou
Independent Non-Executive Director4.3yrsCN¥303.00kNessun dato
Xia Wu
Non-Executive Director5.8yrsNessun datoNessun dato
Guoming Chen
Non-Executive Chairman of the Board4.7yrsCN¥3.16m0.031%
HK$ 638.8k
Junjie Zhang
Non-Executive Director5.8yrsNessun datoNessun dato
Zhixiang Sun
Independent Non-Executive Director4.3yrsCN¥303.00kNessun dato
Jiandong Ding
Independent Non-Executive Director3.8yrsCN¥303.00k0.0012%
HK$ 25.7k

4.3yrs

Durata media

47yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 2160 sono considerati esperti (durata media dell'incarico 4.3 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/05/07 17:11
Prezzo dell'azione a fine giornata2025/05/07 00:00
Guadagni2024/12/31
Guadagni annuali2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

MicroPort CardioFlow Medtech Corporation è coperta da 8 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Yang LuoBOCI Research Ltd.
Sharon ShiBOCI Research Ltd.
Harry HeCGS International